MT1E

Overview

MT1E is a member of the metallothionein family, small cysteine-rich proteins involved in metal homeostasis and stress responses. In HER2+ metastatic esophagogastric cancer, MT1E expression was identified by single-cell RNA-seq as part of a resistance transcriptional program associated with trastuzumab resistance.

Alterations observed in the corpus

  • MT1E expression associated with trastuzumab + chemotherapy resistance by scRNA-seq in HER2+ esophagogastric cancer (EGC) escape lesions; identified alongside MT1H, MT2A, and MSMB as candidate future therapeutic targets PMID:37406106.

Cancer types (linked)

  • Esophagogastric cancer (HER2+) — MT1E expressed in resistance subpopulations at progression on trastuzumab-based therapy PMID:37406106.

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • MT1E is a candidate future therapeutic target; requires orthogonal preclinical validation PMID:37406106.

Open questions

  • The mechanism by which metallothionein isoforms (MT1E, MT1H, MT2A) promote trastuzumab resistance is not fully characterized.

Sources

This page was processed by crosslinker on 2026-05-04.